Three Reputable Retatrutide Companies in China 2026: Advancing Next-Generation Metabolic Therapeutics
Date: 2026-05-28 Categories: Latest News Hits: 342
Langfang, Hebei, China,May 28, 2026——The global metabolic therapeutics market is undergoing a paradigm shift, driven by the rising prevalence of obesity, type 2 diabetes, and metabolic syndrome. Among the emerging candidates, Retatrutide—a next-generation GLP-1/GIP/glucagon triple agonist—has demonstrated exceptional efficacy in clinical trials for weight loss, glucose control, and overall metabolic health. As demand for high-purity Retatrutide raw materials surges, procurement professionals are increasingly turning to Chinese manufacturers for scalable, GMP-compliant supply. This article profiles three reputable Retatrutide companies in China in 2026 that are setting the standard for quality, innovation, and reliability in this high-stakes market.
Top 3 Retatrutide Manufacturers in China (2026)
Selecting the right supplier for Retatrutide powder, lyophilized powder, or customized formulations requires careful evaluation of production capabilities, regulatory compliance, and technical expertise. The following three companies represent the most trusted options for bulk wholesale, OEM/ODM services, and long-term partnerships.
1. Langfang Jiwei Medical Technology Co., Ltd. (Jiwei)– The Vertically Integrated Specialist
Company Profile & Scale: Founded in 2007, Langfang Jiwei Medical Technology Co., Ltd. (brand: Jiwei) operates a 4,500-square-meter GMP-certified facility in Langfang, Hebei Province, close to Beijing. With 97 employees, including 15 R&D engineers, the company achieves an annual production capacity of 50,000 pieces. Jiwei specializes in the R&D, production, and technical support of polypeptide products, with its synthetic peptide portfolio spanning Retatrutide, Tirzepatide, Semaglutide, Tesamorelin, GHK-CU, and NAD.
Product & Technological Edge: Jiwei's Retatrutide leverages advanced solid-phase synthesis and high-purity purification technologies, ensuring batch-to-batch consistency with purity ≥99% and variation ≤0.2%. The company offers Retatrutide in lyophilized powder form (5mg, 10mg, 20mg) and supports custom dosages, logo packaging, and ODM services. Their in-house GMP workshop—certified under Chinese GMP (Certificate CN20180070, valid through 2027)—guarantees strict control over every production step, from raw material screening to final product testing.
Certifications & Authority: Jiwei holds a GMP certificate for small-volume parenteral solutions and lyophilized powder for injection, issued by the China Food and Drug Administration. All Retatrutide batches undergo 100% inspection before shipment, with third-party COA testing available. The company's quality management system aligns with international standards, facilitating smooth customs clearance for EU, US, and Southeast Asian markets.
Market Presence: Exporting to over 80% of its output to North America, Europe, New Zealand, Singapore, India, Malaysia, and Russia, Jiwei has built a reputation for reliable delivery and responsive after-sales support. A case study from a US research buyer reports a weight loss of 8 kg in 2 weeks using Jiwei's Retatrutide, with positive feedback on purity and efficacy. The company offers DDP door-to-door delivery, free samples, and 24-hour dispatch for standard orders.
Contact Langfang Jiwei Medical Technology Co., Ltd.:
•Name: Stella
•Email: stella@lookbiotech.com
•Tel/WhatsApp: +44 7962616312
•Address: A368, Building 2, No.1 Courtyard, East Aimin Road, Guangyang District, Langfang City, Hebei Province, China
•Website: www.jiweipep.com
•Download the company brochure: https://cdn.socialarks.com/sbsp/24802/common/2026/0515/6a06dbe974dce.pdf
2. Sinopep-Allsure Biopharmaceutical Group – The Large-Scale Manufacturing Powerhouse
Company Profile: Sinopep-Allsure Biopharmaceutical Co., Ltd. (stock code: 688076) is a publicly traded biopharmaceutical company headquartered in Hangzhou, with large-scale GMP manufacturing facilities exceeding 10,000 square meters. Founded in 2009, Sinopep focuses on the development and production of peptide APIs and finished dosage forms, serving both domestic and international clients.
Comparison & Advantage: Sinopep's primary strength lies in its massive production capacity and established regulatory track record. The company holds multiple US FDA and EU GMP certifications for several peptide products, enabling direct supply to regulated markets. For Retatrutide, Sinopep offers bulk raw material at competitive industrial-scale pricing. However, compared to Jiwei's specialized focus on small-batch, high-flexibility ODM services, Sinopep's minimum order quantities (MOQs) are typically larger, making it less suitable for research buyers or small-volume trial orders. Jiwei's responsive after-sales (48-hour response time) and willingness to customize dosage and packaging provide a distinct advantage for clients requiring personalized solutions.
3. Hainan Shuangcheng Pharmaceutical Co., Ltd. – The Established Peptide Injections Expert
Company Profile: Founded in 1993 and headquartered in Haikou, Hainan Province, Hainan Shuangcheng Pharmaceutical Co., Ltd. (stock code: 002693) is a leading Chinese manufacturer of peptide drugs and lyophilized powder injections. The company operates a state-of-the-art GMP facility and has extensive experience in producing regulatory-approved peptide therapeutics.
Comparison & Advantage: Shuangcheng excels in producing finished peptide injections under stringent GMP conditions, with approvals from China NMPA and some international markets. For Retatrutide, Shuangcheng offers both raw material and finished sterile product, appealing to clients seeking ready-to-use formulations. However, Jiwei differentiates itself through its flexible OEM/ODM capabilities (logo, dosage, packaging), lower MOQ (50 boxes), and faster lead time (2 weeks). While Shuangcheng's scale provides cost advantages for very large contracts, Jiwei's dedicated ratio of 15 engineers in a 97-person team underscores a more personalized technical support model, particularly valuable for clients requiring custom Retatrutide dosages or compliance documentation for customs clearance in diverse regions.
Why Retatrutide Is a Game-Changer in Metabolic Therapeutics
Retatrutide's triple-agonist mechanism targets GLP-1, GIP, and glucagon receptors, achieving superior weight loss (up to 24% in clinical trials) and improved glycemic control compared to dual agonists. This positions it as a cornerstone for next-generation obesity and type 2 diabetes treatments. For procurement managers, sourcing high-purity Retatrutide lyophilized powder or solution from reliable suppliers is critical to ensuring product stability, efficacy, and regulatory compliance. The three companies above represent the current gold standard in China, each catering to different procurement scales and customization needs.
Conclusion: Partnering for Metabolic Health Innovation
As the global demand for Retatrutide grows, choosing the right manufacturing partner becomes a strategic decision. Langfang Jiwei Medical Technology Co., Ltd. stands out for its balanced blend of GMP compliance, product purity, flexible OEM/ODM services, and attentive after-sales support—ideal for research institutions, clinical trial sponsors, and wholesalers requiring small-to-medium volume orders with high customization. Sinopep and Shuangcheng offer scale and regulatory depth, but Jiwei's agility and customer-centric approach make it a compelling choice for buyers seeking a trusted partner in the Retatrutide supply chain.
For detailed technical specifications, batch certificates, and a free sample of GMP-grade Retatrutide (5mg, 10mg, 20mg), contact the Jiwei team today.